119 related articles for article (PubMed ID: 30197346)
1. Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy.
Doshi KH; Shriyan B; Nookala MK; Kannan S; Joshi A; Noronha V; Gota V; Prabhash K
J Cancer Res Ther; 2018; 14(5):1049-1053. PubMed ID: 30197346
[TBL] [Abstract][Full Text] [Related]
2. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
[TBL] [Abstract][Full Text] [Related]
3. Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.
Cortellini A; Gambale E; Cannita K; Brocco D; Parisi A; Napoleoni L; Masedu F; Irtelli L; De Tursi M; Natoli C; Ficorella C
Thorac Cancer; 2018 Feb; 9(2):241-252. PubMed ID: 29388383
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.
Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ
Med Oncol; 2014 Jul; 31(7):70. PubMed ID: 24927957
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC.
Halvorsen TO; Stokke K; Killingberg KT; Raj SX; Sørhaug S; Brustugun OT; Fløtten Ø; Helbekkmo N; Hornslien K; Madebo T; Fluge S; Grønberg BH
Acta Oncol; 2020 Sep; 59(9):1051-1057. PubMed ID: 32543258
[No Abstract] [Full Text] [Related]
8. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
[TBL] [Abstract][Full Text] [Related]
10. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
Grossi F; Rijavec E; Genova C; Barletta G; Biello F; Maggioni C; Burrafato G; Sini C; Dal Bello MG; Meyer K; Roder J; Roder H; Grigorieva J
Br J Cancer; 2017 Jan; 116(1):36-43. PubMed ID: 27898657
[TBL] [Abstract][Full Text] [Related]
11. Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Germonpré P; Van den Wyngaert T
PLoS One; 2019; 14(4):e0215135. PubMed ID: 30973926
[TBL] [Abstract][Full Text] [Related]
12. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
Yu H; Zhang J; Wu X; Luo Z; Wang H; Sun S; Peng W; Qiao J; Feng Y; Wang J; Chang J
Cancer Biol Ther; 2014 Jul; 15(7):832-9. PubMed ID: 24755888
[TBL] [Abstract][Full Text] [Related]
13. Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Hashemi-Sadraei N; Pennell NA
Curr Treat Options Oncol; 2012 Dec; 13(4):478-90. PubMed ID: 22972369
[TBL] [Abstract][Full Text] [Related]
14. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
[TBL] [Abstract][Full Text] [Related]
16. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
Michelsen L; Sørensen JB
Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
[TBL] [Abstract][Full Text] [Related]
19. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.
Pereira JR; Cheng R; Orlando M; Kim JH; Barraclough H
Drugs R D; 2013 Dec; 13(4):289-96. PubMed ID: 24277116
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]